This company listing is no longer active
Gamida Cell (GMDA.Q) Stock Overview
Researches, develops, and commercializes cell therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GMDA.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gamida Cell Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.017 |
| 52 Week High | US$2.51 |
| 52 Week Low | US$0.008 |
| Beta | 1.13 |
| 1 Month Change | -7.61% |
| 3 Month Change | -95.53% |
| 1 Year Change | -99.13% |
| 3 Year Change | -99.74% |
| 5 Year Change | -99.76% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Gamida Cell shares slide after stock offering
Sep 27Gamida appoints Emergent’s former head of vaccines as new CEO
Sep 19Gamida Cell Q2 2022 Earnings Preview
Aug 12Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel
Aug 01Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?
Feb 23
Gamida Cell: Recapping A Tough Year
Nov 02Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?
Nov 02Shareholder Returns
| GMDA.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | -1.0% | -0.3% |
| 1Y | -99.1% | 26.8% | 15.3% |
Return vs Industry: GMDA.Q underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: GMDA.Q underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| GMDA.Q volatility | |
|---|---|
| GMDA.Q Average Weekly Movement | 38.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GMDA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: GMDA.Q's weekly volatility has increased from 23% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 147 | Abbey Jenkins | www.gamida-cell.com |
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial.
Gamida Cell Ltd. Fundamentals Summary
| GMDA.Q fundamental statistics | |
|---|---|
| Market cap | US$2.62m |
| Earnings (TTM) | -US$61.98m |
| Revenue (TTM) | US$2.67m |
Is GMDA.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMDA.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.67m |
| Cost of Revenue | US$9.14m |
| Gross Profit | -US$6.47m |
| Other Expenses | US$55.51m |
| Earnings | -US$61.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -241.92% |
| Net Profit Margin | -2,317.95% |
| Debt/Equity Ratio | -401.0% |
How did GMDA.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/26 04:38 |
| End of Day Share Price | 2024/05/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gamida Cell Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Cross | Alliance Global Partners |
| Matthew Luchini | BMO Capital Markets Equity Research |
| Jason Butler | Citizens JMP Securities, LLC |